Faruqi & Faruqi Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 11, 2025 - ELV

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elevance Health, Inc. due to allegations of misleading statements regarding Medicaid cost trends and financial guidance, which led to significant stock price declines [2][4][5][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $100,000 in Elevance between April 18, 2024, and October 16, 2024, to discuss their legal options [1]. - A federal securities class action has been filed against Elevance, with a deadline of July 11, 2025, for investors to seek the role of lead plaintiff [2]. Group 2: Allegations Against Elevance - The complaint alleges that Elevance and its executives violated federal securities laws by making false or misleading statements about their monitoring of Medicaid cost trends and the adequacy of premium rates [4]. - On July 17, 2024, Elevance disclosed an expectation of increased Medicaid utilization, resulting in a stock price decline of $32.21 per share, or 5.8% [5]. - Further revelations on October 17, 2024, indicated that Elevance missed EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, leading to a stock price drop of $52.61 per share, or 10.6% [6]. Group 3: Class Action Details - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members and oversees the litigation [7]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [7]. Group 4: Call for Information - Faruqi & Faruqi encourages anyone with information regarding Elevance's conduct, including whistleblowers and former employees, to contact the firm [8].